NLX-204

NLX-204 is a potent and selective small molecule agonist of the serotonin 5-HT1A receptor, developed as a "biased agonist" that preferentially activates specific intracellular signaling pathways. It robustly induces phosphorylation of extracellular signal-regulated kinase (ERK1/2) and cAMP response element-binding protein (CREB), which are associated with rapid antidepressant effects. In preclinical models, NLX-204 demonstrates rapid-onset antidepressant-like activity, reversing depressive behaviors and anhedonia in rodent models subjected to chronic mild stress or corticosterone administration. Its mechanism involves selective activation of cortical 5-HT1A receptors, leading to neurochemical changes in the prefrontal cortex and hippocampus. The drug is being developed by Neurolixis for the treatment of depressive disorders[1][2][4][5][7].